ScandiBio Therapeutics is developing a pharmaceutical drugs that targets mitochondrial dysfunction. Our Lead Product has recently entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer’s disease.
